Live Analyst Rating Changes 21841 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Bailey
MS

David Bailey

Morgan Stanley
Wall Street Analyst
★★★☆☆
#962
on 13Foresight · ranked by our own returns
58%
Success Rate
+7.9%
Average Return
18 of 31 calls profitable · +2.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 58% of David Bailey's ratings turned a profit when each position was held for 1 year — averaging +7.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

57 Buy 24 Hold 20 Sell
David's Stock Coverage 15 ratings · 2026-08-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
 Aug 07, 2026 HOLD Strong Buy
+37.2% avg upside
11 analysts
 — · ·
AU:ANN
Ansell
 Aug 04, 2026 HOLD Buy
-4.8% avg upside
9 analysts
$32.70
5.31% Downside
 +0.0% ·
AU:IDX
Integral Diagnostics Ltd.
 Aug 04, 2026 BUY Strong Buy
+47.3% avg upside
12 analysts
$3.60
69.01% Upside
 -1.8% ·
AU:SHL
Sonic Healthcare Limited
 Aug 04, 2026 SELL Buy
+15.1% avg upside
12 analysts
$20.60
8.05% Downside
 -0.0% ·
AU:RHC
Ramsay Health Care
 Aug 04, 2026 SELL Hold
-7.1% avg upside
14 analysts
$34.60
22.90% Downside
 -3.1% ·
AU:COH
Cochlear
Aug 04, 2026 HOLD Hold
+40.5% avg upside
15 analysts
$123.00
3.20% Downside
 +2.3% ·
AU:CSL
CSL
 Jul 21, 2026 BUY Strong Buy
+42.3% avg upside
16 analysts
$163.00
21.15% Upside
 +12.1% ·
AU:TLX
Telix Pharmaceuticals
 Jul 21, 2026 BUY Strong Buy
+54.2% avg upside
14 analysts
$23.90
43.66% Upside
 +8.9% ·
RMD
Resmed
 Jul 13, 2026 HOLD Buy
+7.1% avg upside
27 analysts
$230.00
5.17% Upside
 +6.8% ·
AU:PME
Pro Medicus Limited
 Aug 15, 2024 BUY Buy
+45.5% avg upside
9 analysts
$152.50
13.73% Downside
 +108.6% ·
AU:HLS
Healius Limited
 Feb 28, 2024 HOLD Sell
+104.9% avg upside
10 analysts
$1.35
229.27% Upside
 +15.8% ·
AU:REG
Regis Healthcare Ltd.
 Jan 31, 2024 BUY Buy
-3.1% avg upside
6 analysts
$3.55
42.76% Downside
 +108.1% ·
SKHHY
Sonic Healthcare
 Aug 24, 2021 HOLD Buy
5 analysts
 — -18.6% ·
AU:PNV
Polynovo
Jan 21, 2021 HOLD Buy
+96.6% avg upside
5 analysts
$2.75
191.06% Upside
 -46.6% ·
AU:MYX
Mayne Pharma Group
 Jan 21, 2021 HOLD Hold
+23.0% avg upside
3 analysts
$0.36
88.88% Downside
 -21.7% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Bailey — Frequently Asked Questions
How accurate are David Bailey's stock ratings?
Based on the calls 13Foresight could measure, about 58% of David's ratings were profitable over a one-year hold, with an average return of +7.9% per rating, or +2.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Bailey is currently ranked #962 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on AU:RMD, AU:ANN, AU:IDX, AU:SHL, AU:RHC, AU:COH, AU:CSL, AU:TLX, RMD, AU:PME, AU:HLS, AU:REG and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.